Alternative strategies more specific to neuroblastoma may involve the direct targeting of the oncogenic miR-17-92 cluster to re-establish DKK3 expression in MYCN amplified neuroblastoma, or the use of agents which directly affect MYCN expression in neuroblastoma cells such as the BET inhibitor, JQ1 (Mertz et al., 2011). This evidence concerns the gene DKK3 and neuroblastoma.